Craig W Spellman

Summary

Affiliation: Texas Tech University Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint Incorporating glucagon-like peptide-1 receptor agonists into clinical practice
    Craig W Spellman
    Department of Internal Medicine, Texas Tech University Health Sciences Center, 701 W Fifth St, Odessa, TX 79763 4206, USA
    J Am Osteopath Assoc 112:S7-15. 2012
  2. pmc Management of progressive type 2 diabetes: role of insulin therapy
    Ramachandra Rahul V Chemitiganti
    Texas Tech University Health Science Center, 701 West 5th Street, Odessa, TX 79763, USA
    Osteopath Med Prim Care 3:5. 2009
  3. ncbi request reprint Achieving glycemic control: cornerstone in the treatment of patients with multiple metabolic risk factors
    Craig W Spellman
    Department of Internal Medicine, Texas Tech University Health Sciences Center, Odessa, TX 79763 4206, USA
    J Am Osteopath Assoc 109:S8-S13. 2009
  4. ncbi request reprint Aggressively managing type 2 diabetes mellitus, hyperlipidemia, and bone loss
    Craig W Spellman
    Texas Tech University Health Sciences Center, Department of Internal Medicine, Odessa, TX 79763 4206, USA
    J Am Osteopath Assoc 108:S20-7. 2008
  5. ncbi request reprint Pathophysiology of type 2 diabetes: targeting islet cell dysfunction
    Craig W Spellman
    Department of Internal Medicine, Texas Tech University Health Sciences Center, Odessa, TX 79763 4206, USA
    J Am Osteopath Assoc 110:S2-7. 2010
  6. ncbi request reprint Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients
    Craig W Spellman
    Center for Diabetes and Metabolic Disorders, Texas Tech University Health Science Center, Midland Odessa, TX 79763 4206, USA
    J Am Osteopath Assoc 111:eS10-4. 2011
  7. ncbi request reprint Combination therapy for dyslipidemia
    Craig W Spellman
    Department of Internal Medicine, University of North Texas Health Science Center at Fort Worth, USA
    J Am Osteopath Assoc 103:S9-11. 2003
  8. ncbi request reprint Islet cell dysfunction in progression to diabetes mellitus
    Craig W Spellman
    Division of Endocrinology at the University of North Texas Health Science Center at Fort Worth Texas College of Osteopathic Medicine, USA
    J Am Osteopath Assoc 107:S1-5. 2007
  9. ncbi request reprint Insulin therapy for maximal glycemic control in type 2 diabetes mellitus
    Craig W Spellman
    Divisions of Internal Medicine and Endocrinology, University of North Texas Health Science Center at Fort Worth, 855 Montgomery St, Fort Worth, TX 76107 2699, USA
    J Am Osteopath Assoc 107:260-9. 2007
  10. ncbi request reprint Management of diabetes in the real world: tight control of glucose metabolism
    Craig W Spellman
    Division of Endocrinology, Diabetes Center, University of North Texas Health Science Center at Fort Worth, TX 76107 2699, USA
    J Am Osteopath Assoc 103:S8-13. 2003

Collaborators

  • Ramachandra Rahul V Chemitiganti

Detail Information

Publications10

  1. ncbi request reprint Incorporating glucagon-like peptide-1 receptor agonists into clinical practice
    Craig W Spellman
    Department of Internal Medicine, Texas Tech University Health Sciences Center, 701 W Fifth St, Odessa, TX 79763 4206, USA
    J Am Osteopath Assoc 112:S7-15. 2012
    ....
  2. pmc Management of progressive type 2 diabetes: role of insulin therapy
    Ramachandra Rahul V Chemitiganti
    Texas Tech University Health Science Center, 701 West 5th Street, Odessa, TX 79763, USA
    Osteopath Med Prim Care 3:5. 2009
    ....
  3. ncbi request reprint Achieving glycemic control: cornerstone in the treatment of patients with multiple metabolic risk factors
    Craig W Spellman
    Department of Internal Medicine, Texas Tech University Health Sciences Center, Odessa, TX 79763 4206, USA
    J Am Osteopath Assoc 109:S8-S13. 2009
    ....
  4. ncbi request reprint Aggressively managing type 2 diabetes mellitus, hyperlipidemia, and bone loss
    Craig W Spellman
    Texas Tech University Health Sciences Center, Department of Internal Medicine, Odessa, TX 79763 4206, USA
    J Am Osteopath Assoc 108:S20-7. 2008
    ..He also strongly recommends incorporating nutrition counseling by registered, licensed dietitians and exercise (preferably of a weight-bearing nature) into treatment plans for patients with T2DM, hyperlipidemia, and low bone mass...
  5. ncbi request reprint Pathophysiology of type 2 diabetes: targeting islet cell dysfunction
    Craig W Spellman
    Department of Internal Medicine, Texas Tech University Health Sciences Center, Odessa, TX 79763 4206, USA
    J Am Osteopath Assoc 110:S2-7. 2010
    ..Emergent therapies for the management of T2DM include incretin-based agents, which can effectively target two key processes in T2DM by augmenting insulin secretion and inhibiting glucagon production...
  6. ncbi request reprint Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients
    Craig W Spellman
    Center for Diabetes and Metabolic Disorders, Texas Tech University Health Science Center, Midland Odessa, TX 79763 4206, USA
    J Am Osteopath Assoc 111:eS10-4. 2011
    ..Concomitant use of dipeptidyl-peptidase-4 inhibitors is not recommended because they have a similar basis of action. Current US Food and Drug Administration indications do not include the concomitant use of GLP-1 agonists with insulin...
  7. ncbi request reprint Combination therapy for dyslipidemia
    Craig W Spellman
    Department of Internal Medicine, University of North Texas Health Science Center at Fort Worth, USA
    J Am Osteopath Assoc 103:S9-11. 2003
    ....
  8. ncbi request reprint Islet cell dysfunction in progression to diabetes mellitus
    Craig W Spellman
    Division of Endocrinology at the University of North Texas Health Science Center at Fort Worth Texas College of Osteopathic Medicine, USA
    J Am Osteopath Assoc 107:S1-5. 2007
    ..In addition, new therapeutic modalities need to address alpha-cell dysregulation, because the inability to suppress glucagon production results in ongoing elevated levels of hepatic glucose...
  9. ncbi request reprint Insulin therapy for maximal glycemic control in type 2 diabetes mellitus
    Craig W Spellman
    Divisions of Internal Medicine and Endocrinology, University of North Texas Health Science Center at Fort Worth, 855 Montgomery St, Fort Worth, TX 76107 2699, USA
    J Am Osteopath Assoc 107:260-9. 2007
    ..Physicians are encouraged to actively identify and address patient concerns about this treatment modality...
  10. ncbi request reprint Management of diabetes in the real world: tight control of glucose metabolism
    Craig W Spellman
    Division of Endocrinology, Diabetes Center, University of North Texas Health Science Center at Fort Worth, TX 76107 2699, USA
    J Am Osteopath Assoc 103:S8-13. 2003
    ....